10-Q: Oncocyte Corporation Reports First Quarter 2024 Results Amidst Strategic Shifts and New Collaborations

Sentiment:

Quarterly Report 15 May 2024 4:06 PM

Oncocyte Corporation's first quarter 2024 results show a net loss of $9.1 million, impacted by decreased revenue and changes in contingent consideration, while the company focuses on strategic shifts and new collaborations.

Capital raiseOncocyte completed a private placement in April 2024, raising approximately $9.9 million after deducting offering expenses and the redemption of preferred stock.The company intends to use the net proceeds from the private placement for general corporate purposes and working capital.The company has historically financed its operations through the sale of common stock, preferred stock, and warrants.

Worse than expectedThe company's net loss of $9.1 million is significantly worse than the net income of $3.0 million in the same period last year.Revenue decreased by 41% year-over-year, indicating a significant downturn in sales performance.The change in fair value of contingent consideration resulted in a $3.3 million loss, further impacting the bottom line.

Summary

Oncocyte Corporation reported a net loss of $9.1 million for the first quarter of 2024, a significant decrease compared to the $3.0 million net income in the same period last year.
The company's revenue decreased to $176,000, down from $297,000 in the first quarter of 2023, primarily due to lower Pharma Services revenue.
Operating expenses totaled $9.2 million, which included a $3.3 million loss from the change in fair value of contingent consideration.
Research and development expenses increased slightly to $2.2 million, while sales and marketing expenses rose to $846,000.
General and administrative expenses decreased to $2.7 million, primarily due to lower stock-based compensation and personnel costs.
The company completed a private placement in April 2024, raising approximately $9.9 million after expenses and the redemption of preferred stock.
Oncocyte is focusing on the development and commercialization of its VitaGraft, DetermaIO, and DetermaCNI tests.
The company has entered into a collaboration agreement with Bio-Rad for the development and commercialization of transplant products.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments like the Bio-Rad collaboration and the private placement, the significant net loss, revenue decline, and going concern uncertainty weigh heavily on the overall sentiment. The company faces significant challenges in achieving profitability and requires further capital to sustain operations.

Positives

Oncocyte secured a positive coverage decision from MolDx for VitaGraft Kidney in August 2023, making it commercially available in January 2024.
The company is actively pursuing the development of DetermaIO, with plans to make it available for clinical use later in 2024.
Oncocyte has entered into a collaboration agreement with Bio-Rad to develop and commercialize transplant products, potentially expanding its market reach.
The company successfully completed a private placement in April 2024, raising approximately $9.9 million, which will support ongoing operations and strategic initiatives.

Negatives

The company experienced a significant net loss of $9.1 million in Q1 2024, a substantial decrease from the net income of $3.0 million in Q1 2023.
Revenue decreased by 41% year-over-year, primarily due to a decline in Pharma Services revenue.
The change in fair value of contingent consideration resulted in a $3.3 million loss, significantly impacting the bottom line.
The company's operating expenses remain high, totaling $9.2 million for the quarter.

Risks

Oncocyte has incurred operating losses and negative cash flows since inception and expects to continue to do so for the foreseeable future.
The company's ability to raise sufficient additional capital to finance its operations depends on various factors, including operating revenues, development progress, and reimbursement coverage.
The unavailability or inadequacy of financing or revenues could force Oncocyte to modify, curtail, delay, or suspend some or all aspects of planned operations.
The company faces risks related to the development and commercialization of new diagnostic tests, including regulatory approvals and market acceptance.
Changes in FDA regulations regarding laboratory-developed tests could result in delays and additional expenses.

Future Outlook

Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. The company plans to complete the development of DetermaIO and make it available for clinical use later in 2024. Oncocyte will also continue to explore commercialization options and seek additional financing to support its operations.

Management Comments

Management intends to complete additional equity financings while maintaining reduced spending levels.
Management plans include further reducing or delaying operating expenses if additional financings are not completed.
Management believes that the fair value of indemnification agreements is minimal.

Industry Context

The announcement reflects the challenges faced by precision diagnostics companies in achieving profitability while navigating regulatory hurdles and market adoption. The collaboration with Bio-Rad indicates a strategic move to leverage partnerships for commercialization and market expansion. The company's focus on transplant and immunotherapy monitoring aligns with growing trends in personalized medicine.

Comparison to Industry Standards

Oncocyte's revenue decline and net loss are concerning when compared to industry leaders in diagnostics, such as Exact Sciences (EXAS) and Guardant Health (GH), which have shown more robust revenue growth and progress towards profitability.
The company's reliance on private placements for funding is not uncommon for early-stage biotech companies, but it highlights the need for stronger revenue generation to achieve long-term sustainability.
The collaboration with Bio-Rad is a positive step, but its success will depend on the effective execution of the Product Development and Commercialization Plans.
Compared to companies like Natera (NTRA) in the transplant monitoring space, Oncocyte's VitaGraft is still in early commercialization, and its market penetration remains to be seen.
The company's focus on DetermaIO in the immunotherapy space is promising, but it faces competition from established players like Foundation Medicine (owned by Roche) and Caris Life Sciences.

Related Party Transactions

Oncocyte entered into a securities purchase agreement with certain investors, including Broadwood, entities affiliated with AWM, Bio-Rad Laboratories, Inc., and certain individuals, including Chairman Andrew Arno.
The company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning & Development.
Oncocyte purchased laboratory equipment and incurred laboratory related expenses from Bio-Rad.

Stakeholder Impact

Shareholders face the risk of further dilution due to potential future equity offerings.
Employees may be affected by potential cost-cutting measures or delays in development programs.
Customers may benefit from the development of new diagnostic tests, but the timeline for commercial availability remains uncertain.
Suppliers may be impacted by changes in the company's financial condition and spending patterns.
Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

Oncocyte will continue to develop and commercialize its VitaGraft, DetermaIO, and DetermaCNI tests.
The company will work with Bio-Rad to develop and commercialize research use only and in vitro diagnostics kitted transplant products.
Oncocyte will seek additional financing to support its operations and strategic initiatives.
The company will focus on obtaining regulatory approvals and reimbursement coverage for its diagnostic tests.

Key Dates

Date	Description
2017-02-28	Date of a loan agreement with Silicon Valley Bank where warrants were issued.
2017-03-31	Date of a loan agreement with Silicon Valley Bank where warrants were issued.
2019-10-31	Date of a loan agreement with Silicon Valley Bank where warrants were issued.
2019-12-23	Date of the Irvine Office Lease Agreement.
2021-04-15	Date of the Chronix Biomedical, Inc. acquisition.
2022-04-13	Date of the Securities Purchase Agreement with institutional accredited investors for Series A Preferred Stock.
2022-12-15	Date of the Stock Purchase Agreement with Dragon Scientific, LLC and Razor Genomics, Inc.
2023-02-16	Date of the completion of the Razor Sale Transaction.
2023-04-03	Date of the agreement with certain members of the Board of Directors and several institutional and accredited investors for the purchase of common stock.
2023-08-08	Date of the Sublease Agreement with Induce Biologics USA, Inc.
2024-01-01	Date of the renewal of the Nashville office leases and addition of a new lease.
2024-04-05	Date of the Collaboration Agreement with Bio-Rad Laboratories, Inc.
2024-04-11	Date of the private placement securities purchase agreement with certain accredited investors.
2024-04-15	Date of the closing of the private placement and redemption of Series A Preferred Stock.
2024-05-07	Date of the number of shares of common stock outstanding.

Keywords

Oncocyte, diagnostics, VitaGraft, DetermaIO, DetermaCNI, transplant, immunotherapy, precision medicine, biopharma, CLIA laboratory, Medicare, reimbursement, private placement, Bio-Rad, collaboration

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.